ATE444293T1 - Cyclische sulfamide zur inhibierung von gamma- sekretase - Google Patents

Cyclische sulfamide zur inhibierung von gamma- sekretase

Info

Publication number
ATE444293T1
ATE444293T1 AT03809796T AT03809796T ATE444293T1 AT E444293 T1 ATE444293 T1 AT E444293T1 AT 03809796 T AT03809796 T AT 03809796T AT 03809796 T AT03809796 T AT 03809796T AT E444293 T1 ATE444293 T1 AT E444293T1
Authority
AT
Austria
Prior art keywords
gamma secretase
inhibiting gamma
cyclic sulfamides
sulfamides
cyclic
Prior art date
Application number
AT03809796T
Other languages
English (en)
Inventor
Ian Collins
Joanne Hannam
Timothy Harrison
Andrew Madin
Mark Ridgill
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE444293T1 publication Critical patent/ATE444293T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT03809796T 2002-11-01 2003-10-31 Cyclische sulfamide zur inhibierung von gamma- sekretase ATE444293T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0225475.3A GB0225475D0 (en) 2002-11-01 2002-11-01 Therapeutic agents
PCT/GB2003/004728 WO2004039800A1 (en) 2002-11-01 2003-10-31 Cyclic sulfamides for inhibition of gamma-secretase

Publications (1)

Publication Number Publication Date
ATE444293T1 true ATE444293T1 (de) 2009-10-15

Family

ID=9947010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03809796T ATE444293T1 (de) 2002-11-01 2003-10-31 Cyclische sulfamide zur inhibierung von gamma- sekretase

Country Status (9)

Country Link
US (1) US7427621B2 (de)
EP (1) EP1611129B1 (de)
JP (1) JP2006508092A (de)
AT (1) ATE444293T1 (de)
AU (1) AU2003276439B2 (de)
CA (1) CA2503884C (de)
DE (1) DE60329533D1 (de)
GB (1) GB0225475D0 (de)
WO (1) WO2004039800A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2304140C2 (ru) 2001-12-27 2007-08-10 Дайити Фармасьютикал Ко., Лтд. ИНГИБИТОРЫ ПРОДУЦИРОВАНИЯ / СЕКРЕЦИИ β-АМИЛОИДНОГО БЕЛКА
RU2336270C2 (ru) 2003-06-30 2008-10-20 Дайити Фармасьютикал Ко., Лтд. Гетероциклические метилсульфоновые производные
CA2539042A1 (en) * 2003-09-24 2005-04-07 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
EP1888050B1 (de) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
US8242103B2 (en) 2005-05-19 2012-08-14 Merck Sharp & Dohme Limited Sulphamides for treatment of cancer
US20080058316A1 (en) 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors
EP2094836B1 (de) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Erzeugung von innerohrzellen
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
GB0813694D0 (en) * 2008-07-25 2008-09-03 Glaxo Group Ltd Compounds
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2488028B1 (de) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (de) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. Sina-zusammensetzungen
JP6486272B2 (ja) 2012-09-07 2019-03-20 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞および／または支持細胞再生のための方法および組成物
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP4076460B1 (de) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
GEAP202516720A (en) 2022-09-02 2025-07-10 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
IL320396A (en) 2022-10-25 2025-06-01 Merck Sharp & Dohme Llc Charge-linkers of anti-drug conjugates derived from extacan, pharmaceutical compositions, and uses thereof
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
HU225960B1 (en) * 1997-02-27 2008-01-28 Takeda Pharmaceutical Amine compounds, their production and use
US7365196B2 (en) * 2000-03-20 2008-04-29 Merck Sharp & Dohme Ltd. Sulphonamido-substituted bridged bicycloalkyl derivatives
DE60112957T2 (de) * 2000-11-02 2006-05-18 Merck Sharp & Dohme Ltd., Hoddesdon Sulfamide als gamma-secretase-inhibitoren
CA2484159C (en) * 2002-05-01 2011-02-22 Merck Sharp & Dohme Limited Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase

Also Published As

Publication number Publication date
JP2006508092A (ja) 2006-03-09
CA2503884A1 (en) 2004-05-13
EP1611129B1 (de) 2009-09-30
US7427621B2 (en) 2008-09-23
WO2004039800A1 (en) 2004-05-13
EP1611129A1 (de) 2006-01-04
GB0225475D0 (en) 2002-12-11
AU2003276439B2 (en) 2009-12-24
US20060135570A1 (en) 2006-06-22
DE60329533D1 (de) 2009-11-12
AU2003276439A1 (en) 2004-05-25
CA2503884C (en) 2011-07-05

Similar Documents

Publication Publication Date Title
DE60329533D1 (de) Cyclische sulfamide zur inhibierung von gamma-sekretase
DE60328182D1 (de) Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
ATE368031T1 (de) Neue gamma secretase inhibitoren
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
ATE302753T1 (de) Sulfamide als gamma-secretase-inhibitoren
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
ATE299890T1 (de) Inhibitoren von gamma-secretase
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
MX2008002234A (es) Inhibidores de sulfonamida n-biciclico puenteados de gamma secretasa.
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE530525T1 (de) Piperidine und verwandte verbindungen zur behandlung von demenz
DK1558580T3 (da) N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
ATE346597T1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
TW200503672A (en) 2-aminobenzoyl derivatives
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
TW200505836A (en) Cyclic sulfonamides for inhibition of gamma-secretase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties